Effects of sitagliptin on blood pressure and heart rate in response to intraduodenal glucose infusion in patients with Type 2 diabetes: a potential role for glucose-dependent insulinotropic polypeptide?

Plain-language guide to PMID 25388434 (2015): double-blind randomized controlled trial study of GIP (Gastric Inhibitory Polypeptide) in 10 people, low blood pressure and orthostatic hypotension.

Key Facts

PMID: 25388434
Journal: Diabetic medicine : a journal of the British Diabetic Association
Year: 2015
Study type: Randomized Controlled Trial
Authors: Wu T et al. (7 authors)
DOI: 10.1111/dme.12622

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of GIP (Gastric Inhibitory Polypeptide) in the context of low blood pressure and orthostatic hypotension, published as a randomized controlled trial.

To evaluate the effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on blood pressure and heart rate, measured during a previously reported study, in which the effects of sitagliptin during intraduodenal glucose infusion at the rate of 2 kcal/min on glucose homeostasis were examined in patients with Type 2 diabetes.

Who Took Part

According to the abstract, 10 people were involved.

By PubMed's age tags, the people studied were older adults, men only.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The people were allocated by chance, so the GIP (Gastric Inhibitory Polypeptide) group and the comparison group should start out alike.

Blinding on both sides kept the people and researchers unaware of who received GIP (Gastric Inhibitory Polypeptide).

The comparison arm used a placebo, so changes seen with GIP (Gastric Inhibitory Polypeptide) could be set against what happens without it.

What Was Measured

The subject headings attached to it are Blood Pressure, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Duodenum, Gastric Inhibitory Polypeptide, Glucose and Heart Rate.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of GIP (Gastric Inhibitory Polypeptide) in 10 people in people with low blood pressure and orthostatic hypotension.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.

More context: the GIP (Gastric Inhibitory Polypeptide) compound page, Low blood pressure and orthostatic hypotension research.

Our Notes on the Compound

GIP (Gastric Inhibitory Polypeptide): A 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.